No trading action warranted; monitor future Form 4 filings for actual buying or selling activity by Bienaime or other insiders, which could signal sentiment shifts
ASND drugs
ASND drug pipeline →How the stock moved after the report
NEUTRAL VIEWSTOCK ABOVE ENTRY AT T+60- T+0 · Apr 2 $229.25entry
- T+1 · 7mo ago −1.12%α −1.59% · $226.69
- T+5 · 7mo ago +4.38%α +0.76% · $239.28
- T+20 · 7mo ago +0.06%α −9.82% · $229.38
- T+60 · 5mo ago +16.34%α +2.18% · $266.72
Price Chart
REPLAYWatch the reaction play outHow similar events traded
Executive Summary
Jean-Jacques Bienaime, a director or significant insider of Ascendis Pharma, filed a Form 3 to report initial beneficial ownership of 9,160 ordinary shares and 172.35 warrants exercisable into shares, with a power of attorney granted to several executives to file SEC reports on his behalf. This is a routine initial filing for ownership disclosure and does not indicate any change in holdings or strategic direction.
Key Facts
- Jean-Jacques Bienaime filed Form 3 to report initial beneficial ownership as of March 23, 2026
- He holds 9,160 ordinary shares (including ADSs) and 172.35 warrants
- Warrants vest 25% on June 10, 2026, then in 36 equal monthly installments through 2035
- Power of attorney granted to six company executives, including CEO, CFO, and CLO, to file SEC forms on his behalf
- Filing is administrative and related to compliance, not a transaction or material event
Financial Impact
No immediate financial impact, ownership levels are small (9,160 shares in a $14.2B company) and no transactions reported
Risk Factors
- Minimal risk, this is a standard disclosure with no operational or financial implications
- Potential misinterpretation of warrant vesting schedule as near-term dilution, though amounts are negligible
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 4 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 3 Filing (Primary) | 0001610717-26-000138 |
| Document: 0001610717-26-000138-index-headers.html | 0001610717-26-000138 |
| Document: 0001610717-26-000138-index.html | 0001610717-26-000138 |
| Document: 0001610717-26-000138.txt | 0001610717-26-000138 |
Track record
41 reports on ASND
14 of 19 bullish or bearish reports moved the stock their way by T+60. Best: +26.62% at T+20 after the Jun 2, 2026 report. 24 of 27 went positive at some point.
Filters
- Nov 16, 2026today SC 13G/A Neutral 3/10 Entry $271.96 Now $271.09 −0.32% settles Feb 12
- Nov 12, 20263d ago 6-K Neutral 2/10 Entry $267.07 Now $271.09 +1.51% settles Feb 11
- Nov 12, 20264d ago 6-K Bullish 6/10 Entry $267.07 Now $271.09 +1.51% settles Feb 10
- Nov 12, 20264d ago Press Release Neutral 5/10 Entry $267.07 Now $271.09 +1.51% settles Feb 10
- Nov 6, 20269d ago 6-K Bullish 6/10 Entry $259.85 Now $271.09 +4.33% settles Feb 5
- Nov 6, 202610d ago Press Release Bullish 6/10 Entry $256.82 Now $271.09 +5.56% settles Feb 4
- Nov 5, 202611d ago SC 13G/A Neutral 2/10 Entry $253.45 Now $271.09 +6.96% settles Feb 3
- Nov 2, 202613d ago Institutional Cluster Bullish 4/10 Entry $250.17 Now $271.09 +8.36% settles Feb 1
- Oct 26, 202621d ago 6-K Bullish 5/10 Entry $245.85 Now $271.09 +10.27% settles Jan 25
- Oct 16, 20264w ago 6-K Bullish 7/10 Entry $225.25 Now $271.09 +20.35% settles Jan 13
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers